Mandate

Vinge advises Eleda in connection with the acquisition of Gatu och Väg Väst AB

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Gatu och Väg Väst AB (“GVV”).

GVV is based in Gunnilse and conducts construction and contracting operations in the south western Sweden, focusing on concrete maintenance work on, inter alia, bridges, power plants and port facilities. GVV has approximately 70 employees and yearly sales of around SEK 240 million. The company’s management team will continue in their respective operational management roles and become shareholders of the Eleda group.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge’s team consisted primarily of partner Christina Kokko and associates Michaela Cronemyr and Carl Fredrik Wachtmeister (M&A), Isak Willborg (Agreements), Ebba Svenburg (Employment), Frida Ställborn (Real Property & Environment), Johan Wahlbom and Joel Kokko (Competition), Tove Lövgren Frisk (Compliance) and Carl Bruneheim (VDR-specialist).

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026